Guggenheim Issues Positive Forecast for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price

Tarsus Pharmaceuticals (NASDAQ:TARS) had its target price boosted by Guggenheim from $89.00 to $97.00 in a report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also issued reports on TARS. Jefferies Financial Group raised their price target on shares of Tarsus Pharmaceuticals from $88.00 to $105.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Barclays started coverage on shares of Tarsus Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “overweight” rating and a $110.00 price target on the stock. Mizuho reduced their price objective on shares of Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a research note on Friday, July 31st. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Finally, Zacks Research raised shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $104.57.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of TARS stock opened at $67.52 on Thursday. Tarsus Pharmaceuticals has a 1-year low of $53.89 and a 1-year high of $91.53. The company has a current ratio of 1.96, a quick ratio of 3.17 and a debt-to-equity ratio of 0.70. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -4.45 and a beta of 0.34. The stock has a 50-day moving average of $75.06 and a 200-day moving average of $67.83.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($14.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by ($12.94). Tarsus Pharmaceuticals had a negative return on equity of 24.51% and a negative net margin of 102.93%. The company had revenue of $194.57 million during the quarter, compared to analyst estimates of $187.83 million. On average, equities research analysts forecast that Tarsus Pharmaceuticals will post -2.23 earnings per share for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, Director William Link, PhD sold 12,500 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $78.38, for a total transaction of $979,750.00. Following the transaction, the director directly owned 94,487 shares in the company, valued at approximately $7,405,891.06. This represents a 11.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Elizabeth Lin sold 10,773 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $87.50, for a total transaction of $942,637.50. Following the sale, the insider directly owned 2,547 shares of the company’s stock, valued at approximately $222,862.50. This trade represents a 80.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 48,031 shares of company stock valued at $4,004,227. 9.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its position in Tarsus Pharmaceuticals by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the period. Parallel Advisors LLC raised its holdings in Tarsus Pharmaceuticals by 139.2% during the first quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock worth $35,000 after buying an additional 291 shares during the last quarter. Covestor Ltd raised its holdings in Tarsus Pharmaceuticals by 40.0% during the third quarter. Covestor Ltd now owns 1,095 shares of the company’s stock worth $86,000 after buying an additional 313 shares during the last quarter. Strs Ohio lifted its stake in shares of Tarsus Pharmaceuticals by 4.8% in the first quarter. Strs Ohio now owns 8,800 shares of the company’s stock valued at $617,000 after buying an additional 400 shares in the last quarter. Finally, Swiss National Bank lifted its stake in shares of Tarsus Pharmaceuticals by 0.8% in the first quarter. Swiss National Bank now owns 62,933 shares of the company’s stock valued at $4,415,000 after buying an additional 500 shares in the last quarter. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 63.9% to about $194.5 million, with record sales of XDEMVY. Tarsus expects $715 million–$730 million in XDEMVY sales for 2026, supporting the growth outlook. Article: Tarsus expects $715M-$730M 2026 XDEMVY sales
• Positive Sentiment: Analysts raised price targets and maintained bullish ratings: Guggenheim lifted its target to $97 with a Buy rating, while Oppenheimer raised its target to $103 and kept an Outperform rating. Guggenheim rating Oppenheimer price target
• Neutral Sentiment: Management plans to participate in upcoming investor conferences; this may provide opportunities to discuss the business and outlook, but no new financial information was announced. Tarsus investor conference announcement
• Negative Sentiment: The quarterly net loss widened to $668 million, primarily due to acquisition-related costs, despite revenue growth. Tarsus also deferred European and Japanese filing plans, delaying potential international expansion. Q3 loss and XDEMVY sales Sales outlook and international filing plans

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye diseases with significant unmet medical needs. The company’s portfolio is centered on therapies designed to address conditions affecting the ocular surface and eyelids.

Tarsus’ lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, an inflammatory eyelid condition associated with an infestation of Demodex mites.